Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEPHAPIRIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEPHAPIRIN SODIUM.
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEPHAPIRIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
1-2 g IV every 8-12 hours; maximum 12 g/day
500 mg to 1 g IM or IV every 6 hours.
None Documented
None Documented
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic